PathScan® Signaling Nodes Multi-Target Sandwich ELISA Kit #7272
- ELISA+
Inquiry Info. # 7272
Please see our recommended alternatives.
Product Specifications
| REACTIVITY | H M |
Application Key:
- ELISA+-ELISA and/or ELISA-like Assays
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
Product Information
Product Description
Antibodies in kit are custom formulations specific to kit.
*See companion products.
实验步骤
Specificity / Sensitivity
Species Reactivity:
Background
MEK1 and MEK2 are dual-specificity protein kinases that function in a mitogen activated protein kinase cascade controlling cell growth and differentiation. Activation of MEK1 and MEK2 occurs through phosphorylation of serine 217 and serine 221 by Raf-like molecules. MEK activates p44 and p42 MAP kinase (8-10).
p38 MAP kinase (MAPK) participates in a signaling cascade controlling the cellular response to pro-inflammatory cytokines and a variety of cellular stresses. MKK3, MKK6 and SEK (MKK4) activate p38 MAP kinase by phosphorylation at Thr180 and Tyr182 (11-14).
The Stat3 transcription factor is an important signaling molecule for many cytokines and growth factor receptors. Stat3 is activated by phosphorylation at Tyr705, which induces dimerization, nuclear translocation and DNA binding (15,16).
Transcription factors of the nuclear factor κB (NF-κB)/Rel family play a pivotal role in inflammation, stress and immune responses. There are five family members in mammals: RelA/p65, c-Rel, RelB, NF-κB1 (p105/p50) and NF-κB2 (p100/p52). These proteins function as dimeric transcription factors. In unstimulated cells, NF-κB/Rel proteins are sequestered in the cytoplasm and inhibited by the IκB proteins. NF-κB-activating agents induce phosphorylation of IκB's, targeting them for degradation and thereby releasing the NF-κB/Rel complexes. Active NF-κB/Rel complexes are further activated by phosphorylation (17-20).
- Kim, D. and Chung, J. (2002) J Biochem Mol Biol 35, 106-15.
- Zdychová, J. and Komers, R. (2005) Physiol Res 54, 1-16.
- Song, G. et al. J Cell Mol Med 9, 59-71.
- Manning, B.D. and Cantley, L.C. (2007) Cell 129, 1261-74.
- Alessi, D.R. et al. (1996) EMBO J 15, 6541-51.
- Sarbassov, D.D. et al. (2005) Science 307, 1098-101.
- Jacinto, E. et al. (2006) Cell 127, 125-37.
- Alessi, D.R. et al. (1994) EMBO J 13, 1610-9.
- McKay, M.M. and Morrison, D.K. (2007) Oncogene 26, 3113-21.
- Pearson, G. et al. (2001) Endocr Rev 22, 153-83.
- Raingeaud, J. et al. (1995) J Biol Chem 270, 7420-6.
- Raman, M. et al. (2007) Oncogene 26, 3100-12.
- Zarubin, T. and Han, J. (2005) Cell Res 15, 11-18.
- Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44.
- O'Shea, J.J. et al. (2002) Cell 109 Suppl, S121-31.
- Kaptein, A. et al. (1996) J Biol Chem 271, 5961-4.
- Ghosh, S. and Karin, M. (2002) Cell 109 Suppl, S81-96.
- DiDonato, J. et al. (1996) Mol Cell Biol 16, 1295-304.
- Sakurai, H. et al. (1999) J Biol Chem 274, 30353-6.
- Mattioli, I. et al. (2004) J Immunol 172, 6336-44.
Alternate Names
Acute-phase response factor; ADMIO; ADMIO1; AKT; AKT serine/threonine kinase 1; AKT1; AKT1 kinase; AKT1m; APRF; CFC3; CMCU; CSAID-binding protein; Csaids binding protein; CSBP; CSBP1; CSBP2; CSPB1; cytokine suppressive anti-inflammatory drug binding protein; Cytokine suppressive anti-inflammatory drug-binding protein; DNA-binding protein APRF; Dual specificity mitogen-activated protein kinase kinase 1; ERK activator kinase 1; EXIP; FLJ20882; HIES; MAP kinase 14; MAP kinase kinase 1; MAP kinase MXI2; MAP kinase p38 alpha; MAP2K1; MAPK 14; MAPK/ERK kinase 1; MAPK14; MAPKK 1; MAPKK1; MAX-interacting protein 2; MEK 1; MEK1; MEL; MGC131774; MGC16063; MGC99656; Mitogen-activated protein kinase 14; mitogen-activated protein kinase kinase 1; Mitogen-activated protein kinase p38 alpha; MK14; MKK1; MP2K1; MXI2; NF-kappa-B p65delta3; NF-kappa-B transcription factor p65; NFkB-p65; NFKB3; Nuclear factor NF-kappa-B p65 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; p38; p38 MAP kinase; p38 mitogen activated protein kinase; p38-alpha; P38A; p38ALPHA; p38alpha Exip; p65; PKB; PKB alpha; PKB-ALPHA; PRKBA; PRKM14; PRKM15; PRKMK1; Protein kinase B; Protein kinase B alpha; protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1); Proto-oncogene c-Akt; RAC; rac protein kinase alpha; RAC-ALPHA; RAC-alpha serine/threonine-protein kinase; RAC-PK-alpha; RELA; RELA proto-oncogene, NF-kB subunit; RELA/p65; RK; SAPK2A; serine-threonine protein kinase; Signal transducer and activator of transcription 3; signal transducer and activator of transcription 3 (acute-phase response factor); STAT3; stress-activated protein kinase 2A; TF65; Transcription factor p65; v-akt murine thymoma viral oncogene homolog 1; v-akt murine thymoma viral oncogene-like protein 1; v-rel avian reticuloendotheliosis viral oncogene homolog A; v-rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (p65)); v-rel reticuloendotheliosis viral oncogene homolog A (avian); v-rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, p65
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专